MyD88 degrader-1
MyD88 degrader-1 is an orally active molecular glue degrader targeting MyD88, with a DC50 of 0.74 μM, and exhibits potent anti-inflammatory activity. MyD88 degrader-1 promotes ubiquitination and proteasomal degradation of MyD88, blocks the activation of the NF-κB signaling pathway, and downregulates the transcription of pro-inflammatory genes such as IL-6 and IL-1β. MyD88 degrader-1 alleviates symptoms in acute lung injury models. MyD88 degrader-1 can be used in studies related to acute lung injury.
For research use only. We do not sell to patients.
- Formula: C23H22N6O6S
- Molecular Weight:510.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
NF-κB |
IL-6 |
IL-1β |
In Vitro
MyD88 degrader-1 (compound d21) potently inhibits LPS-induced IL-6 secretion in J774A.1 mouse macrophages, with an IC50 of 0.42 μM; it also potently suppresses LPS-induced IL-6 secretion in human monocytic THP-1 cells (IC50 = 0.097 μM) and mouse macrophage RAW cells (IC50 = 0.56 μM)[1].
MyD88 degrader-1 (0.125-1 μM; 2 h pretreatment, followed by 6 h LPS stimulation) dose-dependently inhibits LPS-induced transcription of the IL-6 gene in J774A.1 mouse macrophages[1].
MyD88 degrader-1 (0.01-1 μM) induces dose-dependent degradation of MyD88 protein in J774A.1 mouse macrophages, with a DC50 of 0.74 μM[1].
MyD88 degrader-1 (10 μM; 2 h pretreatment followed by 30 min LPS stimulation) inhibits LPS-induced activation of the NF-κB pathway in J774A.1 mouse macrophages by maintaining IκBα levels and reducing p65 nuclear translocation[1].
MyD88 degrader-1 directly binds to and stabilizes MyD88 and RNF126 proteins in J774A.1 mouse macrophages, and promotes the formation of a ternary complex between MyD88 and RNF126 in J774A.1 mouse macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:J774A.1 mouse macrophage cells
-
Concentration:0.125, 0.25, 0.5, 1 μM
-
Incubation Time:0.5 h pretreatment, followed by 24 h LPS stimulation
-
Result:Inhibited 94.55% of LPS-induced IL-6 secretion at 1 μM.
Exhibited an IC50 of 0.42 μM for IL-6 secretion inhibition.
-
Cell Line:J774A.1 mouse macrophage cells
-
Concentration:0.125, 0.25, 0.5, 1 μM
-
Incubation Time:2 h pretreatment, followed by 6 h LPS stimulation
-
Result:Inhibited LPS-induced IL-6 gene transcription in a dose-dependent manner.
Caused significant inhibition at all tested concentrations.
-
Cell Line:J774A.1 mouse macrophage cells
-
Concentration:1 μM
-
Incubation Time:2 h treatment; 1 h MG132 pretreatment before MyD88 degrader-1; 15 min LPS stimulation after pretreatment
-
Result:Significantly reduced MyD88 protein levels when used alone.
Had its degradation effect abrogated by cotreatment with MG132.
Markedly decreased MyD88 abundance under LPS stimulation.
Had its LPS-stimulated MyD88 reduction effect reversed by MG132 (HY-13259).
-
Cell Line:J774A.1 mouse macrophage cells
-
Concentration:10 μM
-
Incubation Time:2 h pretreatment, followed by 30 min LPS stimulation
-
Result:Inhibited LPS-induced NF-κB pathway activation in J774A.1 mouse macrophage cells by preserving IκBα levels and reducing p65 nuclear translocation.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 18-22 g, CLP-induced sepsis model)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; single dose; 30 minutes pre-surgery
-
Result:Reduced CLP group relative lung wet/dry weight ratio, BALF total cell number, BALF and serum IL-6, serum IL-1β, CLP-triggered splenomegaly, and CLP-caused alveolar pathological lesions plus alveolar leukocyte recruitment.
-
Animal Model:C57BL/6 (male, 18-22 g, LPS-induced model)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; single dose; 30 minutes pre-LPS challenge
-
Result:Reduced lung wet/dry weight ratio, BALF total cell count and total protein, systemic and pulmonary IL-6, LPS-triggered splenomegaly, alveolar pathological lesions and alveolar leukocyte infiltration simultaneously.
Chemical Information
-
Molecular Weight 510.52
-
Formula C23H22N6O6S
-
SMILES
NC1=CC=NN1S(=O)(C2=CC=C(C([N+]([O-])=O)=C2)N3CCN(C(/C=C/C(C4=CC=CC=C4)=O)=O)CC3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)